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HapMap imputed genome-wide association studies (GWAS) have revealed >50 loci at which common 
variants with minor allele frequency >5% are associated with kidney function. GWAS using more 
complete reference sets for imputation, such as those from The 1000 Genomes project, promise to 
identify novel loci that have been missed by previous efforts. To investigate the value of such a more 
complete variant catalog, we conducted a GWAS meta-analysis of kidney function based on the 
estimated glomerular filtration rate (eGFR) in 110,517 European ancestry participants using 1000 
Genomes imputed data. We identified 10 novel loci with p-value < 5 × 10−8 previously missed by 
HapMap-based GWAS. Six of these loci (HOXD8, ARL15, PIK3R1, EYA4, ASTN2, and EPB41L3) are 
tagged by common SNPs unique to the 1000 Genomes reference panel. Using pathway analysis, we 
identified 39 significant (FDR < 0.05) genes and 127 significantly (FDR < 0.05) enriched gene sets, 
which were missed by our previous analyses. Among those, the 10 identified novel genes are part of 
pathways of kidney development, carbohydrate metabolism, cardiac septum development and glucose 
metabolism. These results highlight the utility of re-imputing from denser reference panels, until whole-
genome sequencing becomes feasible in large samples.
Chronic kidney disease (CKD) is a major public health concern affecting ~10% of the global adult population1. 
CKD is defined based on the glomerular filtration rate estimated from serum creatinine (eGFRcrea), a quantita-
tive phenotype for which 53 loci have been identified so far by meta-analyses of genome-wide association studies 
(GWAS)2–7. These GWAS meta-analyses were based on ~2.5 million variants imputed from the HapMap Project 
reference panel8. Similar to the genetic variants identified for other phenotypes, all variants associated with eGFR-
crea had a minor allele frequency (MAF) of > 5%. However, though heritability of eGFR has been estimated in 
family studies to range between 36–75%9,10, the identified variants explain less than 4% of the variance of eGFR-
crea7 and are located in regions of extended linkage disequilibrium (LD). So far, causal genes or variants have only 
been identified for a few of the association signals11,12.
It has been shown that variants poorly tagged by GWAS arrays and HapMap imputation, particularly 
low-frequency variants (1% ≤ MAF ≤ 5%), can explain additional variability13. Recent technological advances 
resulted in large collections of whole-genome sequence data, such as those from The 1000 Genomes project14,15. 
These data provide better coverage and increased imputation quality compared to previous HapMap imputa-
tion16, particularly for low-frequency variants.
We undertook a meta-analysis of GWAS from 33 studies that imputed genotypes from The 1000 Genomes 
reference panel, hypothesizing that this would uncover novel common variants associated with eGFRcrea, extend 
to low-frequency variants, reveal novel pathways of eGFRcrea associated genes, and improve fine-mapping of 
known eGFRcrea loci previously identified by our HapMap-based GWAS3–7.
Results
Study characteristics. In total, 110,517 adult individuals of European ancestry from 33 studies participated 
in GWAS meta-analysis of eGFRcrea using genotypes imputed with The 1000 Genomes Phase I reference panel14 
(1000 Genomes meta-analysis). In addition, we performed a GWAS meta-analysis of eGFR derived from cystatin 
C (eGFRcys), an alternative marker of kidney function available in 11 of the 33 studies (n = 24,063). Participating 
studies, phenotypic characteristics, genotype information, and methods of analysis are reported in Supplementary  
Tables 1, 2, 3 and 4, respectively. The 1000 Genome meta-analysis results on eGFRcrea are compared with our 
previously published HapMap imputed data7, which was a HapMap-based meta-analysis of 133,814 European 
ancestry individuals from 50 studies.
Imputation quality of variants imputed with The 1000 Genomes reference panel. The 
1000 Genomes meta-analysis consisted of 10,971,307 genetic variants (10,159,097 SNPs and 812,210 
insertion-deletions) with imputation quality IQ > 0.417 in each of the studies and present in at least 50% of 
the subjects. Depending on the imputation methodology used, the IQ was reported as RSQ18 or info-score19 
(Supplementary Table 3). Compared to the HapMap meta-analysis, the 1000 Genomes meta-analysis included a 
higher number of well imputed variants (8,103,124 versus 2,249,027 variants with IQ > 0.8), particularly among 
the low-frequency variants (1,585,176 versus 191,580, Supplementary Table 5). While rare variants (MAF ≤ 1%) 
were not available in the previous HapMap meta-analysis, there were even 632,526 well-imputed rare variants in 
the 1000 Genomes meta-analysis. When limiting the comparison to variants available in both panels, the propor-
tion of well-imputed variants was higher in the 1000 Genomes compared to the HapMap meta-analysis (96.9% 
versus 93.3% for all; 88.3% versus 78.4% for the less frequent variants, Supplementary Table 5).
1000 Genomes meta-analysis results. The 1000 Genomes meta-analysis identified 49 genome-wide 
significant loci for eGFRcrea including 10 novel loci (lead variant p-value < 5 × 10−8, Table 1, Fig. 1, and 
Supplementary Figure 1). All identified lead variants were SNPs, and all were common, except rs187355703 
near HOXD8 (MAF = 0.03). None of the novel loci contained genes known to cause monogenic forms of kid-
ney disease and for most genes no connection to kidney function or kidney disease has yet been described 
(Supplementary Table 6). However, it should be acknowledged that genetic variants identified in GWAS are not 
necessarily associated with the function of the physically closest gene. Of the 53 known eGFRcrea loci iden-
tified previously based on HapMap2–7, 39 were also genome-wide significant in the current 1000 Genomes 
meta-analysis (Supplementary Table 7) and the remaining 14 showed directions of association consistent with 
published reports, but did not reach significance (p-values 2.2 × 10−2 to 5.2 × 10−7; Supplementary Table 8). These 
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results are consistent with our expectations from power computations (Fig. 2). Among the 39 lead variants in 
previously published loci that were genome-wide significant in the 1000 Genomes meta-analysis, 6 lead variants 
were found to be the same as the previously published variants, 25 were highly correlated (r2 > 0.6), and 8 showed 
moderate or no correlation (r2 ≤ 0.6).
The 1000 Genomes meta-analysis of eGFRcys confirmed previously identified loci in or near CST3/CST9 
(p-value = 4.1 × 10−153), UMOD (p-value = 2.9 × 10−10), and ATXN2 (p-value = 1.6 × 10−8), but did not reveal 
any novel signal.
The ten novel eGFRcrea loci in the context of the different reference panels. For six of the 
ten novel loci (HOXD8, ARL15, PIK3R1, EYA4, ASTN2, and EPB41L3), the lead variant identified in the 1000 
Genomes meta-analysis was not observed in any previous HapMap meta-analysis and in fact was not geno-
typed as part of the HapMap reference panel. Moreover, no variant in LD with any of these six lead variants 
(r2 or D’ ≥ 0.4) was available in the HapMap panel. These loci have been missed due to the limited coverage of the 
HapMap panel.
For one further locus, RHOC, the 1000 Genome meta-analysis lead variant was present also in our previous 
HapMap meta-analysis, but with a lower imputation quality (1000 Genomes median IQ across all studies of 
0.96 versus HapMap median IQ of 0.86). The effect size was slightly higher in the 1000 Genomes compared to 
the HapMap meta-analysis (0.0061 versus 0.0051 ln ml/min/1.73 m2, Supplementary Table 9). This locus might 
have been missed in the HapMap meta-analysis due to the higher uncertainty in the imputed genotypes, which is 
known to diminish power and to attenuate effect size in linear regression20.
For the remaining three loci (LPHN2, SLC7A6 and RNF152), the lead variants of the 1000 Genomes 
meta-analysis were observed in the HapMap meta-analysis and similarly well imputed (IQ near 1.0 for both panels). 
The effect sizes were similar for all three SNPs in both 1000 Genomes and HapMap meta-analyses (0.0057 versus 
0.0041, 0.0061 versus 0.0049, 0.0064 versus 0.0050 ln ml/min/1.73 m2 respectively) and the HapMap estimates 
lie well within the 98.5% confidence interval of the 1000 Genomes estimates. No substantial between-study het-
erogeneity was observed (I2 = 19%, 0%, or 21%, respectively, Supplementary Table 9). Since the p-values in the 
HapMap analysis were just short of genome-wide significance (p-values 8.38 × 10−6 to 2.33 × 10−7; type II error 
of 14–29%), it is conceivable that these variants have been missed previously by chance.
Pathway analyses. Data-driven Expression Prioritized Integration for complex Traits (DEPICT)21 anal-
ysis of eGFRcrea identified 39 significant (FDR < 0.05) genes and 127 significantly (FDR < 0.05) enriched 
gene sets that were not identified previously7. Among those, 23 gene sets contained at least one of the 10 novel 
index genes as a top 10 hit, underpinning the influence of ureteric bud morphogenesis on kidney development 
and the influence of abnormal glucose homeostasis and glucan metabolic process on carbohydrate metabo-
lism (Supplementary Table 10). All 127 significant gene sets were further grouped into meta gene sets, corre-
sponding to their correlation of gene expression. The two most significant meta gene sets were Cardiac Septum 
Development (p-value = 4.48 * 10−5) and Glucose Metabolism (p-value = 6.11 * 10−5), containing one of the 10 
novel index genes (Supplementary Figure 2). We repeated the analysis with varying parameters (50, 200, and 
500 repetitions and 500, 2000, and 5000 permutations, respectively), confirming our primary top gene sets at an 
FDR of < 0.05. P-values ranged from 1.32 × 10−3 to 4.48 × 10−5 and from 8.27 × 10−4 to 4.98 × 10−5 for Cardiac 
Septum Development and Glucose Metabolism, respectively. We replicated also the strong influence of embryonic 
development, kidney transmembrane transporter activity, and kidney and urogenital system morphology in the 
genesis of CKD from our previous findings7: enrichment of all 148 previously identified gene sets was nominally 
significant (p-value < 0.05).
Variant ID Chr Position
Index 
Gene
Effect allele/
non-effect allele
Effect allele 
frequency Effect (SE) p-value I2 (%) IQ
Number of subjects 
in analysis
rs10874312 1 82,944,571 LPHN2 A/G 0.67 − 0.0057 (0.0011) 2.20 × 10−08 19 1.00 107,335
rs12144044 1 113,248,791 RHOC A/C 0.28 − 0.0061 (0.0011) 2.87 × 10−08 0 0.96 110,517
rs187355703 2 176,993,583 HOXD8 C/G 0.97 0.0182 (0.0030) 5.15 × 10−10 5 0.89 109,257
rs111366116 5 53,295,546 ARL15 T/C 0.11 0.0094 (0.0015) 6.27 × 10−10 22 0.97 110,517
rs113246091 5 67,739,274 PIK3R1 A/G 0.10 − 0.0095 (0.0016) 1.98 × 10−09 43 0.98 110,105
rs7764488 6 133,812,872 EYA4 A/G 0.32 0.0061 (0.0011) 4.08 × 10−09 1 0.98 110,516
rs13298297 9 119,264,108 ASTN2 A/G 0.20 − 0.0075 (0.0014) 1.53 × 10−08 0 0.81 110,514
rs1111571 16 68,363,181 SLC7A6 A/G 0.71 0.0061 (0.0011) 6.20 × 10−09 0 1.00 109,275
rs9962915 18 5,593,171 EPB41L3 T/C 0.48 − 0.0055 (0.0010) 7.19 × 10−09 0 0.98 110,516
rs12458009 18 59,350,507 RNF152 T/G 0.78 − 0.0064 (0.0012) 2.90 × 10−08 21 1.00 107,325
Table 1.  The 10 novel genome-wide significant loci (p < 5 × 10−8) associated with eGFRcrea in up to 
110,517 subjects from up to 33 studies. Positions are given on GRCh build 37. The gene closest to the variant 
is listed (index gene). Effect sizes are given on the log scale. IQ = Imputation quality metric computed as 
median of info score (ImputeV2) or RSQ (minimac) across studies. SE = standard error. I2 = between-study 
heterogeneity statistic.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:45040 | DOI: 10.1038/srep45040
Figure 1. Manhattan Plot of the results of the 1000 Genome meta-analysis of eGFRcrea. Shown are the  
(− log10) p-values by genomic position (GRCh build 37). Highlighted are the 10 novel loci identified with 
genome-wide significance (blue, annotated by nearest gene), the 39 previously published2–7 and confirmed 
(genome-wide significant) loci (green) and the 14 previously published loci that were not genome-wide 
significant in this analysis (orange).
Figure 2. Effects of the 1000 Genomes lead variants for all novel and known loci. Shown are the effect sizes 
and minor allele frequencies (MAF) of the 1000 Genomes lead variants (variants with smallest p-value) in each 
of the 10 novel (blue), the 39 known genome-wide significant loci (green), and the 14 known loci that were not 
genome-wide significant in this analysis (orange). Additionally, the 80% power to detect such effects in a sample 
size of 110,000 subjects (as in this 1000 Genomes meta-analysis) is shown as a red line. A known locus is defined 
by the published lead variant ± 1 Mb; a novel locus is defined by the 1000 Genome lead variant ± 1 Mb.
Independent association signals at novel and known loci. To identify independent association 
signals within a known or novel locus, we performed joint conditional analysis of eGFRcrea based on aggre-
gated study-specific statistics using the GCTA software22. Among the combined 49 loci (39 known and 10 novel) 
attaining genome-wide significance, we uncovered eight independent signals, all among the previously reported 
loci, with p-values ranging from 2.39 × 10−8 to 2.78 × 10−17 after conditioning on the lead variants at each locus 
(Supplementary Table 11 and Supplementary Figure 3). We found that in all but one locus (DDX1), the previously 
reported lead variant was also genome-wide significant in our 1000 Genomes meta-analysis. A more detailed 
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reasoning for the independent association signals is proposed in Supplementary Table 12. Information about 
biological knowledge of the highlighted genes is presented in Supplementary Table 13.
Proportion of phenotypic variance explained and polygenic risk score (PRS) analysis. The 
overall proportion of phenotypic variance of eGFRcrea explained by the lead variants of the 1000 Genomes 
meta-analysis in all novel and known loci was 3.99%: 0.46% by the 10 lead variants in the novel loci, 3.12% by the 
39 lead variants in the known loci, and 0.41% by the 1000 Genomes lead variants in the 14 known loci that were 
not genome-wide significant in this analysis.
Next, we tested the proportion of eGFRcrea variance that could be explained by common genetic variants in 
1,071 independent adolescents participating in the TRAILS study. Given prior evidence that eGFRcrea-associated 
genes are preferentially expressed in the kidney and enriched for genes important in kidney development23, exter-
nal influences on eGFRcrea such as those for the two main drivers of CKD, diabetes and hypertension, may 
be less important in this setting. In TRAILS, the maximum proportion of variance explained by SNPs asso-
ciated at pre-defined p-value thresholds was 2.2% for a PRS composed of SNPs associated with eGFRcrea at 
p-value < 1 × 10−5 (Supplementary Table 14).
SNP-based heritability analysis. The heritability estimate using variants of MAF > 0.01 for eGFRcrea 
in the ARIC study was 0.21 (95% CI 0.14–0.28) and 0.31 (95% CI 0.20–0.41) for all variants. This is in line with 
estimates in the literature from population-based family studies such as the Framingham Heart Study (adjusted 
h2 0.33, 95% CI 0.19–0.47)24.
Expression quantitative trait loci (eQTL) lookup. To explore potential functional implications of the 
novel loci, we interrogated published databases of cis eQTL in whole blood25 for the significant SNPs or their 
proxy variants (r2 > 0.8 within a 1 MB window). At 2 novel loci, significant association (p-value < 0.004) with 
gene expression were found: rs1111571 with SLC7A6, ZFP90, LYPLA3 and NFATC3, and for rs12144044 with 
RHOC and ST7L (Supplementary Table 15).
We expanded our downstream analysis by annotating the significant variants with known and predicted reg-
ulatory elements using Regulome DB26: We confirmed rs1111571 and rs12144044 as significant associations with 
gene expression and found supporting evidence that these two variants show also evidence for transcription 
factor binding sites and DNase peaks. For the locus identified by rs187355703 no proxy was found for lookup.
Genetic correlation. To investigate the genetic correlation of serum creatinine with related phenotypes, we 
queried LD Hub27 and identified modest genetic correlation with metabolic syndrome traits such as HDL, LDL, 
Type 2 diabetes, fasting glucose, BMI, and waist (LD score regression genetic correlation between − 0.07 and 
0.05). Little evidence for kidney damage is reported for a risk score of SNPs which are significant predictors of 
blood pressure28.
Discussion
The main finding of our study is that imputing from denser and larger reference panels is a valid strategy to 
advance gene mapping even when the sample size cannot be increased. Using genotype imputation based on The 
1000 Genomes panel led to the identification of 10 novel genome-wide significant loci for kidney function that 
were missed by earlier HapMap-imputed GWAS of larger sample size, partly due to the enhanced coverage of 
genomic variation. This phenomenon was observed in similar analyses of other phenotypes29. Still, it needs to be 
acknowledged that the additional proportion of trait variance explained by these new loci is moderate, which is 
also in line with findings from GWAS of other phenotypes30.
There are several methodological insights that can be gained from our analyses. First, this 1000 
Genomes-based meta-analysis of 110,517 individuals has identified 10 novel loci and 8 independent association 
signals in known loci that were missed by our latest HapMap based analysis7. Our detailed dissection shows 
that 1000 Genomes imputation (i) provides variants missed or poorly tagged by HapMap based analysis and 
(ii) achieves a higher effective sample size through increased imputation quality.
Second, although the 1000 Genomes imputation enables the analysis of low-frequency variants, insertions 
and deletions, all identified top variants were SNPs, and all but one (near HOXD8) were common. Moreover, we 
did not identify any low-frequency variant of large effect. Our results are highly concordant with those of other 
recent complex diseases studies31 showing that low-frequency variants are also contributing to complex disease 
risk, but that most observed effect sizes are small or modest, and hundreds of thousands of subjects are required 
for detection. To identify the contribution of rare variants (MAF < 1%) to eGFRcrea, large-scale sequencing data 
in addition to genomic chip data have been shown to be a promising approach31.
Third, these novel loci, missed by our previous analysis7, extend our knowledge of pathways underlying kidney 
function, which depicts the influence of kidney development, kidney structure, and metabolic activity on the 
development of CKD.
The comparison of our 1000 Genomes meta-analysis with our previous HapMap meta-analysis is limited by 
several factors: the current analysis consists of a reduced number of samples and a slightly different study com-
position. Furthermore, different 1000 Genomes reference panels were used to impute genotypes and advances 
in imputation software and methodology must be acknowledged32,33. Nevertheless, six of the ten lead variants 
in the novel loci are only covered by The 1000 Genomes reference panels, which demonstrates the advantage of 
meta-analyses on 1000 Genomes over HapMap imputed genotypes.
In conclusion, we identified 10 novel loci and 8 additional independent association variants within known loci 
associated with kidney function and identified 127 novel pathways for kidney function. These results highlight 
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the utility of re-imputing studies from improved reference panels as an intermediate cost-efficient approach to 
scan the full allelic frequency range for kidney function associated variants, until whole genome sequencing is 
feasible in large samples.
Methods
Phenotype definition. Each study measured serum creatinine as described in Supplementary Table 1. 
Between-laboratory variation has been accounted for by calibrating creatinine to the US nationally representative 
National Health and Nutrition Examination Study (NHANES) data in all studies4,34,35. GFR based on serum cre-
atinine (eGFRcrea) was estimated using the four-variable Modification of Diet in Renal Disease (MDRD) Study 
Equation36,37. In a subset of studies, serum cystatin C was also obtained and eGFRcys estimated as 76.7*(serum 
cystatin C)−1 19 (see also ref. 38). The eGFRcrea and eGFRcys values < 15 ml/min/1.73 m2 were set to 15, and val-
ues > 200 were set to 200 ml/min/1.73 m2. If not stated otherwise, our presented data and results are for eGFRcrea, 
which was our main analysis.
Genotyping. Genotyping was conducted in each study as specified in Supplementary Table 3. After applying 
appropriate quality filters, participating studies performed genotype imputation with standard imputing pro-
cedures32,33,39 using any version of the 1000 Genome Phase 1 reference panels. The obtained imputed genetic 
variants were coded as allelic dosages. Details of study specific imputation procedure and specific reference panel 
are given in Supplementary Table 3.
Genome-wide association analysis. Each study performed GWAS according to a uniform analysis plan 
by regressing sex- and age-adjusted residuals of the natural logarithm of eGFRcrea and eGFRcys on the allelic 
dosage levels. When appropriate, adjustment for study-specific features such as study site or genetic principal 
components was included in the model. Family-based studies accounted for relatedness using mixed effect mod-
els. Details on the study-specific methods are reported in Supplementary Table 4.
GWAS meta-analysis. All GWAS files underwent quality control using the GWAtoolbox package40. GWAS 
meta-analyses for eGFRcrea and eGFRcys were performed using the software METAL41 assuming fixed effects 
across studies and using inverse-variance weighting, excluding variants with imputation quality IQ ≤ 0.4 or vari-
ants present in less than 50% of the 110,517 subjects (yielding 10,971,307 variants). The genomic inflation factor 
λ was estimated for each study as the ratio between the median of all observed test statistics (b/SE)2 and the 
expected median of a chi-squared with 1 degree of freedom, with b and SE representing the effect of each SNP on 
ln eGFRcrea or ln eGFRcys and its standard error, respectively. Genomic-control (GC) correction42 was applied to 
p-values and SEs in case of λ > 1 (1st GC correction). To limit the possibility of false positives, a second GC cor-
rection on the aggregated results was applied after the meta-analysis. Between-study heterogeneity was assessed 
with the I2 statistic43.
Definition of known and novel loci. Known loci were defined by a previously published lead vari-
ant that had shown genome-wide significant association with eGFRcrea (p-value < 5 × 10−8) and the genetic 
segment around it (lead SNP ± 1 Mb)2–7. Variants outside such segments and associated with eGFRcrea at a 
p-value < 5 × 10−8 in the 1000 Genomes meta-analysis defined the novel loci. Each novel locus was pinpointed by 
the lead variant with the smallest p-value ± 1 Mb.
Comparison of 1000 Genomes and HapMap results. For the variants available in both the 1000 
Genomes and HapMap meta-analyses, we compared lead variants, effect sizes, imputation quality as well as the 
power that we had in the data to detect the respective effects. For this comparison, we also utilized the association 
results of our previous HapMap meta-analysis7 in 50 studies including a maximum of 133,814 subjects. Power 
was calculated in R (www.r-project.org) for the approximate maximum number of subjects in the 1000 Genomes 
meta-analyses (n = 110,000) to identify the lead variants with an alpha of 5 × 10−8. Further, effective power, which 
takes into account the imputation quality of the variant, was calculated based on the effective number of subjects, 
which is the number of subjects per variant multiplied by the median of the imputation quality across studies.
Pathway Analyses. Pathway analyses, comprised of pathway/gene set enrichment and tissue/cell type 
analyses, were performed by applying a software package called Data-Driven Expression Prioritized Integration 
for Complex Traits (DEPICT)21. DEPICT performs gene set enrichment analyses by testing whether genes in 
GWAS-associated loci are enriched for reconstituted versions of known molecular pathways (jointly referred to 
as reconstituted gene sets). The reconstitution is accomplished by identifying genes that are co-regulated with 
other genes in a given gene set based on a panel of 77,840 gene expression microarrays44. Genes that are found to 
be transcriptionally co-regulated with genes from the original gene set are added to the gene set, which results in 
the reconstitution. Several types of gene sets were reconstituted in DEPICT: 5,984 protein molecular pathways 
derived from 169,810 high-confidence experimentally derived protein-protein interactions45, 2,473 phenotypic 
gene sets derived from 211,882 gene-phenotype pairs from the Mouse Genetics Initiative46, 737 Reactome data-
base pathways47, 184 Kyoto Encyclopedia of Genes and Genomes (KEGG) database pathways48 and 5,083 Gene 
Ontology database terms49. In total, 14,461 gene sets were assessed for enrichment in genes in associated regions. 
DEPICT also facilitates tissue and cell type enrichment analyses by testing whether the genes in associated regions 
are highly expressed in any of the 209 MeSH annotations for 37,427 microarrays on the Affymetrix U133 Plus 2.0 
Array platform.
In our analysis, we used DEPICT version 1 rel194 and to be comparable to our previous analysis, included 
all variants reaching eGFRcrea association p-values < 1 × 10−5 from HapMap and 1000 Genomes imputed data 
with genomic coordinates defined by genome build GRCh38 (https://genome.ucsc.edu/cgi-bin/hgLiftOver). 
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Since 1000 Genomes imputed loci in the DEPICT analysis differed slightly from the HapMap imputed loci, our 
HapMap and 1000 Genomes input was created by adding all significant 1000 Genomes variants to all significant 
HapMap variants. This process resulted in a total of 3,659 variants for HapMap, 7,894 variants for 1000 Genomes, 
and 9,270 variants for HapMap and 1000 Genomes analyses. Next, independent lead variants were identified 
with Plink50 using ± 500 kb flanking regions and r2 > 0.01 with the 1000 Genomes data14 as reference. Genomic 
intervals are generated consisting of all variants within r2 > 0.5 to each lead variant. If any of the 19,987 genes in 
the analysis overlaps or resides within a genomic interval, it is mapped to that interval. After merging of overlap-
ping regions and excluding regions within the major histocompatibility complex on chromosome 6, base pairs 
25,000,000–35,000,000, DEPICT analyses were conducted using the following parameters: 200 repetitions to 
compute FDR and 2,000 permutations to compute p-values adjusted for gene length by using 500 null GWAS. For 
the enrichment analysis we used 10,968 reconstituted gene sets. For visualization, all novel significant gene sets 
were further merged into meta gene sets by running an affinity propagation51 from Pythons scikit-learn package 
(http://scikit-learn.org/). The network was visualized with Cytoscape (http://cytoscape.org/).
Identification of independent association signals with GCTA. We searched for independent associ-
ation signals in the known and novel loci with a joint conditional analysis on the aggregated meta-analysis results 
using the GCTA-COJO method (conditional and joint genome-wide association analysis)22,52. The KORA-F4 
GWAS data53 were used to estimate the LD (r2) in the joint conditional analysis, and to quantify the extent of 
coinheritance (D’)50. A potential independent association signal within a given locus was reported if the variant 
with the smallest conditional p-value was genome-wide significant (p-value < 5 × 10−8) after conditioning on the 
previously reported variant in a locus.
SNP-based heritability analysis. The heritability of eGFRcrea was estimated using GCTA GREML-LDMS 
methods54 (version 1.25) with imputed genotype accounting for linkage disequilibrium. The imputed genotype 
was based on dosage (probability > 0.9) imputed using the 1000 Genomes Phase I reference panel and filtered by 
the following criteria: HWE < 1 × 10−6, individual missingness > 5%, SNP missingness > 5%, and MAF < 0.0005 
(~3 copies).
Proportion of phenotypic variance explained. To quantify the impact of the identified genetic loci on 
renal function, the percent of phenotypic variance explained by all lead variants in the novel and known loci was 
estimated as ∗Beta var variant
var eGFRcrea
( )
(resid(ln( ) ) )
2 , where var (variant) = 2 * MAF * (1− MAF)and beta is the estimated effect of the 
variant in the 1000 Genomes meta-analysis55. The variance of the residuals of ln (eGFRcrea) is computed in the 
ARIC study (n = 9,038). All variants were assumed to have independent effects on the phenotype.
Polygenic risk score analysis. PriorityPruner (http://prioritypruner.sourceforge.net) was used to select 
independent SNPs from The 1000 Genomes reference panel using an algorithm that preferentially selects 
SNPs that are more significant in the current 1000 Genomes meta-analysis compared to the previous HapMap 
meta-analysis. Polygenic risk scores (PRSs), using various thresholds of significance, as obtained from the 1000 
Genomes meta-analysis results and weighted for the effects sizes within study were generated in TRAILS56 
(n = 1,071), an independent study of adolescents, which was not part of the meta-analysis. These PRSs were tested 
for association with eGFRcrea using linear regression in R and the variance explained by the PRSs was calculated.
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